公开(公告)号：US20200330459A1

公开(公告)日：2020-10-22

申请号：US16089842

申请日：2017-04-05

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  OSAKA UNIVERSITY

发明人： Geneviève DERUMEAUX ,  Daigo SAWAKI ,  Gabor CZIBIK ,  Takehiko YOSHIMITSU

IPC分类号： A61K31/4985 ,  C12N15/113 ,  A61K39/395 ,  A61P9/00 ,  A61P3/00

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.

公开(公告)号：US20220088015A1

公开(公告)日：2022-03-24

申请号：US17463664

申请日：2021-09-01

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  OSAKA UNIVERSITY

发明人： Geneviève DERUMEAUX ,  Daigo SAWAKI ,  Gabor CZIBIK ,  Takehiko YOSHIMITSU

IPC分类号： A61K31/4985 ,  A61P3/00 ,  A61P9/00 ,  A61K39/395 ,  C12N15/113

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.